Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Imagine ... all the possibilities
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Comment by Marky1on Mar 07, 2021 9:58pm
223 Views
Post# 32740730

RE:RE:RE:RE:RE:RE:RE:RE:Imagine ... all the possibilities

RE:RE:RE:RE:RE:RE:RE:RE:Imagine ... all the possibilitiesI believe in the long term positive conclusion of this long and tortuous journey we've all been on...We have the goods, the science is real, p values cannot be argued because that's what they were designed to do..give conclusive evidence of the  failure  ( high P value ) or success ( low P values) of the drug that they are testing. We have a man who's entire life's work is coming to a head! The man is the kingpin of GI ulceration / inflammation disturbances caused by a soon to be classified (hopefully ) group of drugs as dangerous and potentially life threatening.

We have the personnelle, men that Dan Legault has recruited, Don Haut and Joe Stauffer are unbelievable assets to the company. We have Stern working for us.. getting the word out to American institutions, Big Pharma, and setting the stage for our jump to the Nasdaq exchange.
so,in summary...we have the INS to the FDA, to Bayer, to American deep pockets.
2021 is going to be amazing!
GLTA
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities